Kiora Pharmaceuticals
KPRX
9 hedge funds and large institutions have $209K invested in Kiora Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 6 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
0.39% more ownership
Funds ownership: 0.02% → 0.41% (+0.39%)
31% less funds holding
Funds holding: 13 → 9 (-4)
47% less capital invested
Capital invested by funds: $391K → $209K (-$182K)
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$121K |
| 2 |
Morgan Stanley
New York
|
+$20.5K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$12.3K |
| 4 |
SFM
Spartan Fund Management
Toronto, Ontario,
Canada
|
+$8.67K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.81K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$31K |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$24K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$22K |
| 4 |
Renaissance Technologies
New York
|
-$20K |
| 5 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
-$7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
BlackRock
New York
| $89K | +$121K | +1,549 | +2,671% |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $86K | +$2.81K | +36 | +2% |
|
|
3
Morgan Stanley
New York
| $15K | +$20.5K | +263 | +26,300% |
|
|
4
UBS Group
Zurich,
Switzerland
| $13K | +$12.3K | +158 | +198% |
|
|
SFM
5
Spartan Fund Management
Toronto, Ontario,
Canada
| $6K | +$8.67K | +111 | New |
|
|
6
Vanguard Group
Malvern,
Pennsylvania
| – | -$31K | -187 | Closed |
|
|
7
T. Rowe Price Associates
Baltimore,
Maryland
| – | -$24K | -143 | Closed |
|
|
8
Citadel Advisors
Miami,
Florida
| – | -$22K | -129 | Closed |
|
|
9
Renaissance Technologies
New York
| – | -$20K | -116 | Closed |
|
|
10
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| – | -$7K | -42 | Closed |
|
|
TRCT
11
Tower Research Capital (TRC)
New York
| – | -$6K | -35 | Closed |
|
12
US Bancorp
Minneapolis,
Minnesota
| – | -$78 | -1 | -13% |
|
13
Wells Fargo
San Francisco,
California
| – | +$78 | +1 | New |
|
KPRX Hedge Fund Activity: Q3 2022 in Review
9 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Kiora Pharmaceuticals (KPRX) for Q3 2022, worth a combined $209K — down 47% from $391K a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of KPRX and 2 opened new positions — a net loss of 4 holders — while 1 trimmed existing stakes and 4 added.
The largest buyer was BlackRock, adding an estimated $121K. The largest seller was Vanguard Group, exiting entirely with an estimated $31K sold.
- 9 institutional investors held Kiora Pharmaceuticals (KPRX) as of Q3 2022, down from 13 in Q2 2022.
- Funds reported $209K of Kiora Pharmaceuticals stock for Q3 2022, down 47% quarter-over-quarter.
- 2 funds opened new Kiora Pharmaceuticals positions in Q3 2022 and 6 closed out, a net change of -4 holders.
- The largest Kiora Pharmaceuticals buyer in Q3 2022 was BlackRock, an estimated $121K added.
- The largest Kiora Pharmaceuticals seller in Q3 2022 was Vanguard Group, an estimated $31K sold.
Based on aggregated 13F filings for Q3 2022.